Skip to content
ClinCalc Pro
Menu
Nitroimidazole — Anaerobic Infections / C. difficile / Giardia / Dental Infections Pregnancy: 'There is inadequate evidence of the safety of metronidazole in pregnancy but it has been in wide use for many years without apparent ill consequence. Nevertheless metronidazole, like other medicines, should not be given during pregnancy or during lactation unless the physician considers it essential; in these circumstances the short, high-dosage regimens are not recommended' (§4.6).

Metronidazole (Paediatric)

Brand names: Flagyl, Metronidazole Suspension

Metronidazole (paediatric) is an antimicrobial used in children for anaerobic bacterial infections and certain protozoal infections, including intra-abdominal and dental infections, C. difficile and giardiasis. This page covers its use in the paediatric population.

Auto-extracted from the source labelling — not yet independently clinician-verified. These values were distilled from the UK SPC (or the US label where noted) but have not had a clinician sign-off. Confirm against the current SmPC before prescribing.

Adult dose

Dose: Treatment of established anaerobic infection: 800 mg followed by 400 mg 8 hourly
Route: Oral — tablets should be swallowed with water (not chewed), taken during or after a meal
Frequency: Every 8 hours; the duration of a course is about 7 days but depends on the clinical and bacteriological severity
SOURCE: eMC UK SPC, productName 'Metronidazole 200 mg Film-Coated Tablets', §4.2. FORMULATION CAVEAT: this is the ORAL tablet SPC — intravenous and rectal regimens are not covered by this source (§4.2 only notes that surgical prophylaxis is 'followed by postoperative intravenous or rectal administration until the patient is able to take tablets'). VERBATIM anaerobic treatment: 'Adults 800 mg followed by 400 mg 8 hourly.' SURGICAL PROPHYLAXIS (adults): '400 mg 8 hourly during 24 hours immediately preceding operation.' OTHER ADULT INDICATIONS from the §4.2 table (adults and children over 10 years): urogenital trichomoniasis — 2000 mg as a single dose, or 200 mg three times daily, or 400 mg twice daily (7 or 5–7 days; where re-infection is likely the consort should receive a similar course concurrently); bacterial vaginosis — 400 mg twice daily for 5–7 days or 2000 mg as a single dose (1 day); amoebiasis invasive intestinal disease in susceptible subjects — 800 mg three times daily for 5 days; intestinal disease in less susceptible subjects and chronic amoebic hepatitis — 400 mg three times daily for 5–10 days; amoebic liver abscess and other extra-intestinal amoebiasis — 400 mg three times daily for 5 days; symptomless cyst passers — 400–800 mg three times daily for 5–10 days; giardiasis — 2000 mg once daily for 3 days, or 400 mg three times daily for 5 days, or 500 mg twice daily for 7–10 days; acute ulcerative gingivitis — 200 mg three times daily for 3 days; acute dental infections — 200 mg three times daily for 3–7 days; leg ulcers and pressure sores — 400 mg three times daily for 7 days. ELDERLY: well tolerated, but a pharmacokinetic study suggests cautious use of high dosage regimens in this age group. MONITORING: regular clinical and laboratory monitoring (especially leucocyte count) if treatment beyond 10 days is considered necessary (§4.4). Source §4.4 and §4.8 were truncated at the source-fetch limit and §4.5 was not retrieved.

Paediatric dose

Dose: 7.5 mg/kg
Route: Oral
Frequency: Every 8 hours in children over 8 weeks to 12 years of age; every 12 hours in children under 8 weeks of age
Max: No single overall paediatric cap is stated. Indication-specific limits given in §4.2: urogenital trichomoniasis — 'not to exceed 2000mg/dose'; amoebiasis dosed by body weight — 35 to 50 mg/kg daily in 3 divided doses for 5 to 10 days, 'not to exceed 2400mg/day'; Helicobacter pylori eradication in paediatric patients — 20 mg/kg/day 'not to exceed 500 mg twice daily' for 7–14 days as part of combination therapy
The 7.5 mg/kg figure is the per-DOSE component of the divided regimen for established anaerobic infection. VERBATIM §4.2: children over 8 weeks to 12 years of age — 'The usual daily dose is 20-30mg/kg/day as a single dose or divided into 7.5mg/kg every 8 hours. The daily dose may be increased to 40mg/kg, depending on the severity of the infection. Duration of treatment is usually 7 days.' Children under 8 weeks of age — '15mg/kg as a single dose daily or divided into 7.5mg/kg every 12 hours.' In newborns with a gestational age under 40 weeks, accumulation can occur during the first week of life, so serum metronidazole concentrations should preferably be monitored after a few days of therapy. SURGICAL PROPHYLAXIS: children under 12 years — 20–30 mg/kg as a single dose given 1–2 hours before surgery; newborns with a gestational age under 40 weeks — 10 mg/kg body weight as a single dose before operation. PROTOZOAL INFECTIONS (fixed doses by age band, §4.2 table): trichomoniasis in children — 40 mg/kg orally as a single dose or 15–30 mg/kg/day divided in 2–3 doses; giardiasis children 7–10 years 600–800 mg once daily, 3–7 years 500 mg once daily, or alternatively 15–40 mg/kg/day divided in 2–3 doses; amoebiasis, gingivitis and other indications have separate fixed doses for the 7–10, 3–7 and 1–3 year bands. 'Children and infants weighing less than 10 kg should receive proportionally smaller dosages.' Verify all under-18 dosing against a children's formulary.

Dose adjustments

Renal

'The elimination half-life of metronidazole remains unchanged in the presence of renal failure. The dosage of metronidazole therefore needs no reduction.' Such patients retain the metabolites of metronidazole, the clinical significance of which is not known. In patients undergoing haemodialysis, metronidazole and its metabolites are efficiently removed during an eight-hour dialysis period, so metronidazole should be re-administered immediately after haemodialysis. No routine dose adjustment is needed in renal failure patients undergoing intermittent peritoneal dialysis or CAPD. Substantial impairment of metronidazole clearance may occur in advanced hepatic insufficiency, with significant accumulation in hepatic encephalopathy (§4.4).

Dose auto-extracted from UK Summary of Product Characteristics (SPC) via the eMC; US FDA prescribing information (openFDA / DailyMed) — cross-check; US labelling may differ from UK — not yet clinician-verified. Always confirm against the product SmPC and your local formulary before prescribing.

Paediatric weight-based calculator

The 7.5 mg/kg figure is the per-DOSE component of the divided regimen for established anaerobic infection. VERBATIM §4.2: children over 8 weeks to 12 years of age — 'The usual daily dose is 20-30mg/kg/day as a single dose or divided into 7.5mg/kg every 8 hours. The daily dose may be increased to 40mg/kg, depending on the severity of the infection. Duration of treatment is usually 7 days.' Children under 8 weeks of age — '15mg/kg as a single dose daily or divided into 7.5mg/kg every 12 hours.' In newborns with a gestational age under 40 weeks, accumulation can occur during the first week of life, so serum metronidazole concentrations should preferably be monitored after a few days of therapy. SURGICAL PROPHYLAXIS: children under 12 years — 20–30 mg/kg as a single dose given 1–2 hours before surgery; newborns with a gestational age under 40 weeks — 10 mg/kg body weight as a single dose before operation. PROTOZOAL INFECTIONS (fixed doses by age band, §4.2 table): trichomoniasis in children — 40 mg/kg orally as a single dose or 15–30 mg/kg/day divided in 2–3 doses; giardiasis children 7–10 years 600–800 mg once daily, 3–7 years 500 mg once daily, or alternatively 15–40 mg/kg/day divided in 2–3 doses; amoebiasis, gingivitis and other indications have separate fixed doses for the 7–10, 3–7 and 1–3 year bands. 'Children and infants weighing less than 10 kg should receive proportionally smaller dosages.' Verify all under-18 dosing against a children's formulary.

Verify in a children's formulary

Contraindications

  • Known hypersensitivity to nitroimidazoles, metronidazole or any of the excipients

Side effects

  • Nausea, vomiting, epigastric pain, diarrhoea, taste disorders, oral mucositis and furred tongue (frequency not known)
  • Peripheral sensory neuropathy or transient epileptiform seizures during intensive and/or prolonged therapy — in most cases neuropathy disappeared after treatment was stopped or the dose reduced; also drowsiness, dizziness, convulsions and headaches (very rare)
  • Encephalopathy and subacute cerebellar syndrome (ataxia, dysarthria, gait impairment, nystagmus, tremor), which may resolve on discontinuation (very rare); aseptic meningitis (not known)
  • Increase in liver enzymes, cholestatic or mixed hepatitis, hepatocellular liver injury, jaundice and pancreatitis, reversible on drug withdrawal (very rare); severe hepatotoxicity/acute hepatic failure in patients with Cockayne syndrome (§4.4)
  • Skin rashes, pustular eruptions, acute generalised exanthematous pustulosis, pruritus and flushing (very rare); erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis and fixed drug eruption (not known); darkening of urine due to a metronidazole metabolite (very rare)

Interactions

  • Disulfiram — psychotic reactions reported in alcoholic patients using metronidazole and disulfiram concurrently; metronidazole should not be given to patients who have taken disulfiram within the last two weeks (US label, Drug Interactions)
  • Alcoholic beverages or products containing propylene glycol — abdominal cramps, nausea, vomiting, headaches and flushing may occur during or following metronidazole therapy (US label)
  • Warfarin and other oral coumarin anticoagulants — anticoagulant effect potentiated with prolongation of prothrombin time; monitor prothrombin time and INR carefully (US label)
  • Lithium — short-term metronidazole in patients on relatively high doses of lithium has been associated with elevated serum lithium and signs of lithium toxicity; check serum lithium and creatinine several days after starting metronidazole (US label)
  • Busulfan — plasma concentrations of busulfan increased, with increased risk of busulfan toxicity (US label)
  • NOTE: the UK SPC §4.5 interaction section was NOT retrieved in this source bundle — the interactions above are taken from the US label and must be verified against the UK SPC

Clinical monograph

How it works

Within susceptible anaerobic bacteria and protozoa it is reduced to reactive intermediates that damage microbial DNA, leading to cell death.

Prescribing in practice

  • The most important paediatric counselling point is that alcohol (including in liquid medicines and some mouthwashes) must be avoided during and shortly after treatment because of a disulfiram-like reaction.
  • Prolonged or repeated courses carry a risk of peripheral and central neurotoxicity, so duration should be limited and the indication reviewed.
  • Dose is weight-based and available by oral, intravenous and rectal routes; doses should be confirmed against a children's formulary, with caution in hepatic impairment.

Monitoring

Monitor for neurological symptoms (numbness, tingling, ataxia) and hepatic function on prolonged courses, alongside clinical response.

Counselling the patient

  • Avoid all alcohol during the course and for a short period afterwards to prevent flushing, nausea and palpitations.
  • Report any numbness, tingling, unsteadiness or persistent headache.
  • Complete the full course as prescribed even if the child feels better.

Evidence & guidelines

Metronidazole is a long-established first-line agent for anaerobic and several protozoal infections, with its alcohol interaction and neurotoxicity risk well documented.

Reference: NICE NG199 (C. difficile); PHE Antibiotic Guidelines; IDSA/SHEA C. difficile Guidelines 2021; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. The structured dose values shown have been reviewed by a clinician. Monograph status: clinician-reviewed (2026-07-04).

Related

Curated clinical cross-links plus same-class fallbacks.